The username/email didn't match the password, please try again!

Forgot your password?

The email you have inserted is not registered at Medicon Valley Online. If you wish to gain access to a specific organization profile please speak to one of the registered contacts of that organization. The registered contacts can usually be found on the profile page of that organization.

The email you have inserted is not in our database. Plese try again!

To add a compound to a pipeline your organisation needs to be registered as a biotech or pharmaceutical company at Medicon Valley Online. If your organisation is already registered please click on the Sign in button below. If you wish to register a new organisation, please click the Register button.

To add a service your organisation needs to be registered at Medicon Valley Online as a member of Medicon Valley Alliance and have paid the one time fee of 2300 EUR for the service section. If this has been accomplished please, just click the Sign in button below. If you want access to the services section or media about it please send your contact details to contact@mediconvalleyonline.com and we will get back to you.

Email
Password

(Uncheck if on a shared computer)
Forgot your password?
Create Account
Please enter your email address in the field below. Once submitted a message, with an authorization link, will be sent to this address so that you can set a new password for your account. You will have access to you account again in a couple of minutes. Thank you for your patience.
Medicon Valley Online
Home
  
Organisations
  
Drug Pipeline
  
Contract Services
 Email  Print  PDF  Bookmark | | More
View all organisations

Camurus AB

Biotech Company / Delivery

Pipeline
Staff
Contact
 MVA
Member of Medicon Valley Alliance

description Description

Camurus specialises in the development of pharmaceuticals based on advanced nanoscale delivery solutions that optimize the therapeutic performance of difficult substances, including peptides and proteins. The company's FluidCrystal® delivery systems are used in developments programs with biotech and pharmaceutical companies worldwide. Camurus also develops own drug products targeting improved performance, safety, and patient compliance of well-documented drug compounds. New candidates for oral mucositis, prostate cancer, and acromegaly are currently in clinical trials.

Drug Pipeline

compound Episil® [Internal project]

Episil® represents a new concept for local treatment of pain associated with oral mucositis. The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal® film that mechanically protects the sensitised and sore epithelium of the oral cavity. Episil® is conveniently administered from a ready to use multi-dose device.

Read more about Episil® go

Drug development

Therapeutical Area / Indication Pre-
clinical		 Phase
I		 Phase
II		 Phase
III		 Phase
IV
Mouth and Tooth Diseases
primary Mucositis Pre-clinical Phase I Phase II Phase III Phase IV

compound CAM2029 [Co-developed with Novartis]

CAM2029 is a new ready-to-use, long-acting octreotide product for treatment of acromegaly and carcinoid tumours (and other gastro-entero-pancreatic neuroendocrine, GEP NE, tumours). The product consists of a lipid-based liquid administered subcutaneously as a low volume injection. Once injected the lipid constituents immediately start to self-assemble into the "active" FluidCrystal® controlled release matrix. Therapeutic plasma levels of octreotide are thereby rapidly reached and maintained over one month. CAM2029 has been designated orphan drug status by EMEA.

Read more about CAM2029 go

Drug development

Therapeutical Area / Indication Pre-
clinical		 Phase
I		 Phase
II		 Phase
III		 Phase
IV
Gland and Hormone Related Diseases
primary Acromegaly Pre-clinical Phase I Phase II Phase III Phase IV
Cancers and Other Neoplasms
Malignant Carcinoid Syndrome Pre-clinical Phase I Phase II Phase III Phase IV

compound CAM2038 [Internal project]

CAM2038 represents a new treatment concept for opiate addiction based on the well-documented anti-addiction therapeutic buprenorphine. While the current buprenorphine products on the market rely on frequent administrations of sublingual buprenorphine tablets, CAM2038 is based on a once-weekly or once-monthly subcutaneous administration that can be given by health-care professional in a clinical setting. This allows for better treatment compliance and safeguards against misuse and drug diversion. In October 2011, Camurus completed a Phase I/II trial of CAM2038 in opioid addicted patients. The investigational drug was found to be well tolerated both systemically and locally at all doses tested in the trial and no safety concerns were identified in the safety population (n=41). The pharmacodynamics readouts, subjective and clinical opiate withdrawal symptoms (SOWS and COWS), were well controlled for up to 10 days after single-dose injection of CAM2038.

Read more about CAM2038 go

Drug development

Therapeutical Area / Indication Pre-
clinical		 Phase
I		 Phase
II		 Phase
III		 Phase
IV
Behaviors and Mental Disorders
primary Opioid-Related Disorders Pre-clinical Phase I Phase II Phase III Phase IV

compound Prosenze® [Internal project]

CAM2032 is a new convenient ready-to-use, long-acting leuprolide formulation being developed for long-term treatment of prostate cancer, with development also initiated for endometriosis. The product consists of a lipid-based solution filled on standard pre-filled syringes and compatible with autoinjector devices. It is administered as a low volume subcutaneous injection that rapidly transforms in situ into the "active" FluidCrystal® controlled release matrix, providing consistent plasma levels over time. CAM2032 is being developed in two product forms, a one-month depot followed by a three-month product. Results from a Phase II clinical trial of Prosenze® in patients with advanced metastatic prostate cancer demonstrate that CAM2032 gives a clinically significant and effective suppression of testosterone during the 28 day treatment period. Moreover, the treatment was safe and well tolerated.

Read more about Prosenze® go

Drug development

Therapeutical Area / Indication Pre-
clinical		 Phase
I		 Phase
II		 Phase
III		 Phase
IV
Cancers and Other Neoplasms
primary Prostatic Neoplasms Pre-clinical Phase I Phase II Phase III Phase IV

compound CAM2036 [Internal project]

Read more about CAM2036 go

Drug development

Therapeutical Area / Indication Pre-
clinical		 Phase
I		 Phase
II		 Phase
III		 Phase
IV
Nutritional and Metabolic Diseases
primary Diabetes Mellitus, Type 2 Pre-clinical Phase I Phase II Phase III Phase IV

Staff Top top

Fredrik Tiberg
Fredrik Tiberg
President & CEO
fredrik.tiberg@camurus.com
vCard
Liselotte Larsson
Liselotte Larsson
Senior Director, Business Development and Alliances
liselotte.larsson@camurus.com
vCard

Contact Top top

Camurus AB
Tel: +46 46 286 57 30
Fax: +46 (46) 286 57 39
www.camurus.com

Address:
Sölvegatan 41
SE-223 62
Lund
Sweden
©2010 Medicon Valley Online - Brought to you by Medicon Valley Alliance. All rights reserved.